New study watches Real-World use of thyroid cancer drugs

NCT ID NCT05733013

Recruiting now Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is gathering information from 100 adults with a type of thyroid cancer that no longer responds to standard radioactive iodine treatment. Doctors are using special medications called redifferentiating agents to try to make the cancer respond again. The goal is to track how well these drugs work and what side effects occur when they are used in regular medical practice, not just in a research setting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma refractory malignant neoplasm thyroid cancer thyroid gland disorder Thyroid Neoplasms thyroid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY THYROID CANCER THYROID THYROID CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact Phone: •••-•••-••••